UBS’s CORMEDIX INC WTS EXP 04/30/15 CRMD.WS Stock Holding History

UBS’s Portfolio CRMD.WS Stock Details CRMD.WS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$1K	Sell	2,828 -100	-3%	-$30	﹤0.01%	10253
2014 Q2	$1K	Buy	2,928 +1,241	+74%	+$515	﹤0.01%	10320
2014 Q1	$1K	Sell	1,687 -5,700	-77%	-$3.06K	﹤0.01%	10309
2013 Q4	$1K	Buy	7,387 +3,130	+74%	+$369	﹤0.01%	10279
2013 Q3	$0	Buy	4,257 +1,000	+31%	+$104	﹤0.01%	11080
2013 Q2	$1K	Buy	+3,257	New	+$519	﹤0.01%	10114

Other funds holding CRMD.WS

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UBS's CRMD.WS Position: Q3 2014 in Review

UBS reduced its CORMEDIX INC WTS EXP 04/30/15 (CRMD.WS) stake by 3.4% in Q3 2014, selling an estimated $30 and leaving 2,828 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #10253.

UBS first reported a position in CRMD.WS in Q2 2013 and has held it in 6 quarters since. 4 funds tracked by Wall St. Rank hold CRMD.WS as of Q3 2014.

UBS held 2,828 shares of CORMEDIX INC WTS EXP 04/30/15 worth $1K as of Q3 2014.
UBS sold 100 CORMEDIX INC WTS EXP 04/30/15 shares in Q3 2014, an estimated $30.
CORMEDIX INC WTS EXP 04/30/15 made up ﹤0.01% of UBS's portfolio in Q3 2014, its #10253 holding.
UBS first reported a position in CORMEDIX INC WTS EXP 04/30/15 in Q2 2013 and has held it in 6 quarters since.
4 funds tracked by Wall St. Rank held CORMEDIX INC WTS EXP 04/30/15 as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.